NasdaqGM:PAHCPharmaceuticals
A Look At Phibro Animal Health (PAHC) Valuation After Strong Earnings And Zoetis MFA Integration
Phibro Animal Health (PAHC) is back on investors’ radar after reporting earnings and revenue that surpassed expectations, supported by stronger vaccine sales and the integration of Zoetis’ MFA business, which is reinforcing interest in its animal health portfolio.
See our latest analysis for Phibro Animal Health.
The share price has reacted strongly to this run of positive updates, with a 30 day share price return of 15.9% and a 90 day share price return of 44.7%. This has contributed to a...